effect of human umbilical cord mesenchymal stem cell adjuvant therapy on liver function and fibrosis indicators as well as the degree of inflammation in patients with hepatitis b cirrhosis
Clicks: 466
ID: 219989
2016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
466 views
47 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #9 of 96 articles by views in journal of communications
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Objective: To analyze the effect of human umbilical cord mesenchymal stem cell adjuvant
therapy on liver function and fibrosis indicators as well as the degree of inflammation in
patients with hepatitis B cirrhosis. Methods: A total of 80 cases with hepatitis B cirrhosis
in our hospital from August 2012 to November 2014 were included for study. According to
different treatment methods, all included patients were divided into observation group and
control group by half. Control group received conventional treatment, observation group
received human umbilical cord mesenchymal stem cell adjuvant therapy, and then differences
in the levels of liver function indicators, liver fibrosis indicators, inflammation-related
indicators and illness-related indicators were compared between two groups. Results: Serum
ALB, GLB and A/G values of observation group after treatment were higher than those of
control group, and α2-M, TB, APO-A1 and GGT values were lower than those of control
group (P<0.05); serum HA, LN, CIV, PⅢNP and PLD values of observation group after
treatment were lower than those of control group (P<0.05); serum TGF-β1, PCT, WBC and
SIL-2R levels of observation group after treatment were lower than those of control group
(P<0.05); serum FT3 and ADP values of observation group after treatment were higher than
those of control group, and NO, EGF, ADM and IR values were lower than those of control
group (P<0.05). Conclusions: Human umbilical cord mesenchymal stem cell adjuvant
therapy for patients with hepatitis B cirrhosis can optimize liver function and inhibit disease
progression, and it has active clinical significance.
| Reference Key |
luo2016journaleffect
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Gui-Jin Luo;Ping-Guang Lei |
| Journal | journal of communications |
| Year | 2016 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.